Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor/tezacaftor/ivacaftor) for the ...

Envudeucitinib, another allosteric TYK2 inhibitor, also achieved PASI 75 in 70-75% of patients at 16 weeks and PGA 0/1 status ...

A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...

Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.

For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant ...